Since magnetic particles have unique features, the development of a variety of medical applications has been possible. The most unique feature of magnetic particles is their reaction to a magnetic force, and this feature has been utilized in applications such as drug targeting and bioseparation including cell sorting. Recently, magnetic nanoparticles have attracted attention because of their potential as contrast agents for magnetic resonance imaging (MRI) and heating mediators for cancer therapy (hyperthermia). Magnetite cationic liposomes (MCLs), one of the groups of cationic magnetic particles, can be used as carriers to introduce magnetite nanoparticles into target cells since their positively charged surface interacts with the negatively charged cell surface; furthermore, they find applications to hyperthermic treatments. Magnetite nanoparticles conjugated with antibodies (antibody-conjugated magnetoliposomes, AMLs) are also applied to hyperthermia and have enabled tumor-specific contrast enhancement in MRI via systemic administration. Since magnetic nanoparticles are attracted to a high magnetic flux density, it is possible to manipulate cells labeled with magnetic nanoparticles using magnets; this feature has been applied in tissue engineering. Magnetic force and MCLs were used to construct multilayered cell structures and a heterotypic layered 3D coculture system. Thus, the applications of these functionalized magnetic nanoparticles with their unique features will further improve medical techniques.
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Magnetic particles ranging from the nanometer to micrometer scale are being used in an increasing number of medical applications. The important properties of magnetic particles for medical applications are nontoxicity, biocompatiblilty, injectability, and high-level accumulation in the target tissue or organ; the most important property among those mentioned above is nontoxicity. Ferrous or ferric oxide is the main constituent of magnetic particles, although metals such as cobalt and nickel are used in other fields of application. Magnetic particles are attracted to high magnetic flux density; this feature is used for drug targeting and bioseparation including cell sorting. Currently, magnetic nanoparticles are attracting attention because of their potential use as contrast agents for magnetic resonance imaging (MRI) and heating mediators for cancer thermotherapy (hyperthermia). Furthermore, a novel application of magnetic nanoparticles and magnetic force for tissue engineering, termed "magnetic force-based tissue engineering (Mag-TE)" has been proposed. This review mainly focuses on the medical applications of magnetic nanoparticles in MRI, hyperthermia, and Mag-TE.
I. MAGNETIC SEPARATION
The processes of isolation and separation of specific molecules are used in almost all areas of biosciences and biotechnology, and are the most documented and currently the most useful application of magnetic particles. Various magnetic particles have been developed as magnetic carriers in separation processes including purification and immunoassays (1-9). Liu et al. (10) also demonstrated that the population of nitrifying bacteria increased in the water treatment process in which magnetic particles conjugated with a positively charged polymer matrix were used. The binding of specific ligands to magnetic particles is the same as with other carriers comprising a polymer matrix. Separation techniques are extremely important in process engineering such as bioprocessing.
Automatic DNA/RNA purification apparatuses are commercially available for laboratory use. With respect to medical applications, magnetic cell sorting was developed for use in cellular therapy. In the removal of a specific cell population from blood by conventional immunoaffinity column chromatography, other dominant blood cells cause interference (11) . In blood purification, the elimination of specific cytokines such as interleukin-1 or tumor necrosis factor, which are the major pathogenic mediators in septic shock and multiorgan failure, has been proposed (12) .
Magnetic particles are also used in immunoassays (13, 14) . Immunoassays are widely used for medical examinations (e.g., detection of viruses or assay of various hormones) (15, 16) . Magnetic separation is a suitable method to reduce the duration of both adsorption and separation steps (17) .
Nagatani et al. (18) reported a unique approach for transfecting cells using magnetite cationic liposomes (MCLs) associated with a plasmid vector and the selection of transformants using a magnetic field. In clinical applications, somatic cells that are transformed to produce specific proteins should be rapidly selected on account of the limited number of cell divisions. Therefore, the rapid selection of transformants among a transiently transformed population is important. Selection using antibiotic-resistance marker genes is, however, time consuming; furthermore, the recovery of the transformants cannot be guaranteed, because the transformation efficiency depends on the cell line used. When MCLs associated with a plasmid vector were transfected into mouse NIH/3T3 cells, the specific activity of the luciferase gene transfectants was approximately 7-fold higher than that of the cells before separation using the magnetic field. Some researchers have reported the separation of transiently transfected cells using magnetic particles associated with antibodies (19) (20) (21) . However, this method requires the cotransfection of a gene for the expression of a surface marker. In the method developed by Nagatani et al. (18) , the expression of an additional marker is not required for separation, and magnetic separation can be performed immediately after transformation. This is a major advantage for the separation of transformants.
II. MAGNETIC RESONANCE IMAGING AND CANCER DIAGNOSIS
The applications of MRI have steadily increased over the past decade. MRI offers the advantage of high spatial resolution of contrast differences between tissues. Due to the unique function of this imaging modality, there is a need to develop effective contrast agents that will enhance and widen its diagnostic utility. Paramagnetic ion chelates and ferromagnetic or superparamagnetic nanoparticles, with sizes that generally range between 3 and 10 nm, have been developed as MR contrast agents and used in clinical diagnosis. In most situations, they are used for their effects, which result in signal reduction on T 2 -weighted images ("negative" contrast).
During recent years, there has been an increase in interest regarding the use of magnetic nanoparticles as contrast agents, such as dextran magnetite in MRI (22, 23) . In comparison to paramagnetic ions, super-paramagnetic iron oxide particles have higher molar relaxivities, and when used as blood pool and tissue-specific agents, they may offer advantages at low concentrations (24, 25) .
Commercial contrast agents do not have active targeting ability, but are useful for enhancing the contrast differences of the liver or spleen because magnetic nanoparticles accumulate in the reticuloendothelial system such as the liver and spleen (passive targeting). Suzuki et al. (26) studied the specific distribution of these agents by active targeting. Monoclonal antibodies (MAbs) specifically targeted to cancer cells could serve as a possible tool for active targeting. They developed an MRI contrast agent, MAb-magnetite (Fig. 1A) , which was prepared by covalently linking polyethylene glycol-coated magnetite to a MAb specific for a human glioma cell surface antigen. When MAb-magnetite was injected intravenously into tumor-bearing nude mice, magnetite nanoparticles accumulated in the tumor tissue 24 or 48 h after the MAb-magnetite injection, and a 50% decrease in the T 2 signal intensity of the tumor was observed as shown in Fig. 1B (26) .
Shinkai et al. (27) and Uchiyama et al. (28) have proposed a direct sensing method for magnetic nanoparticles in cancer diagnosis. They developed a small and highly sensitive magnetic sensor, the magneto impedance (MI) sensor, for the sensing of tumor tissue that incorporates magnetic particles. They attempted to detect magnetic particles in a rat glioma, a malignant brain tumor, transplanted under the skin of a rat's leg (27) . The magnetic nanoparticles in the tumor were magnetized by a static magnetic field generator at 1.8 T. The magnetic field distribution of the magnetic nanoparticles was detected using the MI sensor; furthermore, its distribution indicated that the magnetic nanoparticles were localized only in the tumor. When these apparatuses are available for clinical use, the diagnosis of metastatic cancer with high sensitivity will be possible.
III. MAGNETIC-NANOPARTICLE-INDUCED HYPERTHERMIA
"Quae medicamenta non sanat; ferrum sanat. Quae ferrum non sanat; ignis sanat. Quae vero ignis non sanat; insanabilia reportari oportet" -Hippocrates.
(Those diseases which medicines do not cure, the knife cures; those which the knife cannot cure, fire cures; and those which fire cannot cure, are to be reckoned wholly incurable.)
As Hippocrates (460-370 BC) described in his aphorism, he believed that any disease could be cured by heating the patient's body. Hyperthermia is a promising approach to cancer therapy, and various methods inducing hyperthermia, such as the use of hot water, capacitive heating, and induction heating among others, have been employed (29) (30) (31) (32) . A major technical problem with the application of hyperthermic treatments is the difficulty in heating the local tumor region to the intended temperature without damaging normal tissue. Conventional hyperthermic systems are designed to heat tissue to approximately 42.5°C to 44.0°C. However, higher temperatures can kill a greater number of tumor cells, and in principle, tumor-specific hyperthermia can kill all types of tumor cells.
Some researchers have proposed the concept of "intracellular" hyperthermia and have developed submicron magnetic particles for inducing hyperthermia (33) (34) (35) . This concept is based on the principle that under an alternating magnetic field (AMF), a magnetic particle can generate heat by hysteresis loss. In 1979, Gordon et al. (36) first proposed the concept of inducing intracellular hyperthermia using dextran magnetite nanoparticles. They administered magnetite nanoparticles intravenously to Sprague-Dawley rats bearing mammary carcinomas and showed that AMF-induced heating occurred in their in vivo experiments. Jordan et al. (37) have proposed magnetic fluid hyperthermia in several other comprehensive in vitro studies.
The important properties of magnetic particles for inducing hyperthermia are nontoxicity, biocompatibility, injectability, high-level accumulation in the target tumor and effective absorption of the energy of AMF. Chan et al. (38) reported on modified dextran magnetite and its hyperthermic effect by using several human carcinoma cell lines in vitro. The specific absorption rate (SAR), which indicates the heat evolution rate in hyperthermia, of conventional dextran magnetite is low. Dextran magnetite behaves as a super-paramagnetic particle rather than a ferromagnetic particle due to its small size; hence, its hysteresis loss is very low. Chan et al. (38) controlled the oxygen concentration in the preparation of dextran magnetite and selected particles of approximately 15 nm. Shinkai et al. (39) have reported that particle size is a critical factor in obtaining a high SAR value.
IV. HYPERTHERMIA USING MAGNETITE CATIONIC LIPOSOMES
Since the administered particles passively migrate to a reticuloendothelial system such as the Kupffer cells of the liver and spleen, the passive targeting of magnetic nanoparticles for cancer is a very important issue. With regard to the drug delivery of magnetic nanoparticles, magnetoliposomes may be a promising tool for passive targeting. This type of vesicle consists of magnetic nanoparticles wrapped in a phospholipid bilayer (liposome). Liposomes have structural and biokinetic advantages such as their ability to encapsulate therapeutic drugs or genes. Furthermore, the liposomal surface could be chemically modified in order to enable targeting to a specific tissue. Since the localization of vesicles in tumor cells can be enhanced by their surface charge, Shinkai et al. (40) developed MCLs ( Fig. 2A ) with improved adsorption and accumulation properties. As shown in Fig. 2B , MCLs, which have a positive surface charge, showed a 10-fold higher affinity for rat glioma cells as compared to neutrally charged magnetoliposomes. MCLs have a sufficiently high SAR and a general biocompatibility that are comparable to those of dextran magnetite. The Kobayashi research group demonstrated the efficacy of hyperthermia by using MCLs in animals with several types of tumors, such as the B16 mouse melanoma (41), T-9 rat glioma (42), Os515 hamster osteosarcoma (43) , and VX-7 squamous cell carcinoma in rabbit tongue (44) .
In an experimental model using T-9 rat glioma (42), MCLs were injected into solid tumors formed subcutaneously in F344 rats. Subsequently, the rats were exposed to an AMF for 30 min once (group II), twice (group III), or three times (group IV). In the control group (group I), the rats were administered MCLs but were not exposed to AMF. The temperature of the tumor was rapidly elevated by AMF exposure and it exceeded 43°C after 15 min, as shown in Fig. 2C . In contrast, the rectal temperature or the temperature in a tumor lacking the MCLs remained between 35-37°C. In group II, the decrease in the average tumor volume was not significant. However, in the case of groups III and IV, in which the animals received repeated AMF exposure, the average tumor volume decreased markedly.
Complete regression was observed in one of the five rats in group II, three of the five in group III, and seven of the eight in group IV. This confirmed the effectiveness of multiple AMF exposures in attaining tumor regression. In group IV, only one tumor exhibited no regression. Figure 2D shows the time courses of tumor growth. The tumor volume in control rats (no AMF exposure) steadily increased with no evidence of regression. In contrast, complete tumor regression was observed in many of the rats subjected to three AMF exposures, at 24-h intervals. In most cases of complete regression, the tumor volume increased up to the 12th day, after which it began to decrease and the tumor finally disappeared. No regrowth of tumors was observed following complete regression over a period of 3 months.
To achieve complete tumor regression, multiple AMF exposure is very important. Ito et al. (45) showed that com-plete regression of mammary carcinomas of a size greater than 15 mm by frequent repeated hyperthermic treatments using MCLs was obtained in all mice. In these studies, 40-60% of the injected MCLs accumulated in the tumor tissue, whereas only 20-25% of the neutral magnetoliposomes accumulated. This high accumulation of MCLs is considered to be due to the cationic charge on the surface of the liposome used. Furthermore, a significant hyperthermic effect was achieved.
V. HYPERTHERMIA USING ANTIBODY-CONJUGATED MAGNETITE NANOPARTICLES
Administration of the MCLs is limited to direct injection into the tumor tissue. If magnetic nanoparticles adsorb only to cancer cells, the particles could be administered intravenously. This feature would be of great advantage in terms of the quality of life of patients, and would enable cancer diagnosis by MRI and concurrent hyperthermic treatment (the proposed therapeutic strategy using the magnetic particles is illustrated in Fig. 3 ). The conjugation of antibodies to magnetic particles is a possible approach to achieving such an aim.
Le et al. (46) and Shinkai et al. (47) have developed magnetite nanoparticles conjugated to the Fab' fragments of anti-human MN antigen-specific antibody and their hyperthermic effects were demonstrated using a mouse renal cell carcinoma model. Human MN antigen is a cell-surface antigen frequently expressed in clear-cell type renal cell carcinoma, but not detected in normal kidney. The Fab' fragment of the G250 antibody that binds to the MN antigen on many types of human renal cell carcinomas was cross-linked to N-(6-maleimidocaproyloxy)-dipalmitoylphosphatidylethanolamine (EMC-DPPE) in the liposomal membrane. The targeting ability of the G250 antibody-conjugated magnetoliposomes (G250-AMLs, Fig. 4A ) was investigated using a mouse renal cell carcinoma (mRCC) and MN antigen-presenting cells, MN antigen-overexpressing mouse renal cell carcinoma (MN-mRCC) (47) . In an in vivo experiment using MN-mRCC-harboring mice, 7.9 mg of the AMLs per gram of carcinoma tissue (the tumor weight: 0.19 g) were found to be accumulated, which corresponded to approximately 50% of the total amount injected (Fig. 4B) . After injection of the AMLs, the mice were subjected to AMF exposure. The temperature of the tumor tissue increased to 43°C and the growth of the carcinoma was significantly arrested for at least 2 weeks (Fig. 4C) . These results indicate that the G250-AMLs could target the renal cell carcinomas in vitro and in vivo, and that they are suitable for the efficient hyperthermic treatment of carcinomas.
FIG. 2. Magnetite cationic liposomes (MCLs) for hyperthermia. Magnetite nanoparticles were wrapped in cationic liposomes (A). (B) Comparison of magnetite uptake by T-9 rat glioma cells in vitro between MCLs (closed circles) and neutrally charged magnetoliposomes (MLs, open circles). For the in vivo experiment (C), MCLs were directly injected into a subcutaneous T-9 tumor, and an alternating magnetic field (AMF, 118 kHz and 384 Oe) was applied for 30 min. Temperature increases of the outer covering of the tumor (closed circles) and of the rectum (open circles) during magnetic field irradiation. (D)
The time courses of the tumor growth. In nonexposed animals, the tumor volume in each rat steadily increased with no evidence of regression. In contrast, complete tumor regression was observed in 88% of the rats that were exposed three times to the AMF. Tumor regrowth over a 3-month period was not observed following complete regression. Each line represents an individual rat. Schematic illustration of the therapeutic strategy using magnetic particles. Functionalized magnetic nanoparticles accumulate in the tumor tissues via the drug delivery system (DDS). Magnetic nanoparticles can be used as a tool for cancer diagnosis by magnetic resonance imaging (MRI) or for magnetoimpedance (MI) sensor. Hyperthermia can then be induced by AMF exposure. Thus, magnetic nanoparticles can be used for cancer therapy at the same time as diagnosis.
FIG. 4.
Antibody-conjugated magnetoliposomes (AMLs) for active targeting. Magnetite nanoparticles were wrapped in a neutral liposome, and a G250 antibody was covalently linked to the liposomal surface (A). (B) Magnetite uptake of G250-AMLs for carcinomas and various organs 48 h after the intraarterial injection of AML (0.4 ml, net magnetite: 3 mg). Animals in group I (open columns), i.e., the control group, were transplanted with MN antigen-overexpressing mouse renal cell carcinoma (MN-mRCC) and injected with magnetoliposomes (MLs). Group II animals (closed columns) were transplanted with MN-mRCC and the G250-AMLs were injected. (C) Photographs of a kidney 14 d after the hyperthermic treatment for MN-mRCC (left)-or mouse renal cell carcinoma without MN antigens (mRCC; right)-bearing mice. Forty-eight hours after the injection, the mice were exposed to a magnetic field (118 kHz and 384 Oe), and the treatment was repeated three times at 24-h intervals. 6 
VI. ANTITUMOR IMMUNITY INDUCTION BY HYPERTHERMIA USING MAGNETITE NANOPARTICLES
Interestingly, Yanase et al. (48) observed that tumor-specific hyperthermia using magnetite nanoparticles induced antitumor immunity. They demonstrated this event by transplanting a tumor to each femur of a rat. MCLs were directly injected into only one tumor and the hyperthermic treatment was applied. The temperature at the MCL-injected tumor increased to 45°C, whereas that at the other tumor did not increase. However, both the tumors disappeared completely after 28 d (Fig. 5A) . Immunocytochemical assay revealed that CD8-positive and CD4-positive T cells migrated to both tumors after the hyperthermic treatment. These results suggest that therapeutic magnetite nanoparticles are potentially effective tools for hyperthermic treatment of tumors, because in addition to the killing of tumor cells by heat, a host immune response is induced. To explain how tumor antigens are recognized by the host immune system, Kobayashi and coworkers (49) (50) (51) proposed heat shock protein (HSP)-mediated antitumor immunity as a mechanism.
Hyperthermia is known to induce HSPs (52) . Since the expression of HSPs protects cells from heat-induced apoptosis (53), HSP expression is considered to be a complicating factor in hyperthermia. On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90 and glucose-regulated protein 96, in immune reactions. Furthermore, investigators have suggested that HSPs chaperone tumor antigens (54, 55) . With regard to the mechanism of antitumor immunity induced by hyperthermia using MCLs, Kobayashi and coworkers (49, 50) have demonstrated two possible mechanisms of antigen presentation via HSP70 expression during hyperthermia. One possible mechanism is the presentation of antigenic peptides by the tumor cells via MHC class I molecules.
Srivastava and coworkers (56) (57) (58) proposed the following "relay line model" for tumor antigenic peptide transfer during antigen processing and presentation by HSPs: (i) The peptides are first bound to HSP70 (or HSP90), which are responsible for transporting them to the endoplasmic reticulum (ER) through the transporter associated with antigen processing (TAP); (ii) the peptides are transferred to gp96 in the lumen of the ER; (iii) in the terminal step, gp96 transfers the peptides to the MHC class I-β 2 microglobulin complexes. Wells and coworkers (59, 60) demonstrated that stably transfected B16 melanoma cells that constitutively expressed the human HSP70 exhibited significantly increased levels of the MHC class I antigens on their surface. Ito et al. (49) revealed that the augmentation of MHC class I antigens on the tumor cell surface via HSP70 expression caused the induction of immunity. The HSP70 expression level peaked 24 h after heating, and the augmentation of MHC class I surface expression level started 24 h after heating and peaked 48 h after heating. The expression of other immunologic mediators, such as intracellular adhesion molecule-1 (ICAM-1) and MHC class II antigens, did not increase. In an in vivo experiment using syngenic rats, the growth of the heated T-9 cells accompanied by the augmentation of MHC class I antigen surface expression level was significantly inhibited; on the other hand, the cells grew progressively in nude rats. Furthermore, in comparison with lymphocytes from nonimmunized rats or rats injected with nonheated T-9 cells, the splenic lymphocytes of the rats injected with the heated T-9 cells displayed specific cytotoxicity against the T-9 cells. These results suggest that HSP70 is an important modulator FIG. 5. Antitumor immune response induced by hyperthermia using magnetite nanoparticles. (A) Rats photographed on the 28th day after the MCL injection. Rat glioma T-9 cells (1×10 7 cells) were transplanted subcutaneously into the left femoral region of F344 rats. On the 9th day after transplantation into the left side, another aliquot of the T-9 cell suspension (1 ×10 7 cells) was transplanted subcutaneously into the right femoral region. The MCLs were injected into the left tumor only, on the 11th day after the first transplantation. When hyperthermic treatment was repeated three times at 24-h intervals, both tumors had disappeared by the 28th day after the MCL injection. (B) The hypothesis for the mechanism of immune response after hyperthermic treatment using magnetite nanoparticles. See text for details. of tumor cell immunogenicity during hyperthermia. An alternative mechanism for the recognition of tumor cell antigens by the host immune system in hyperthermia is the cross-presentation of antigenic peptides by professional antigen presenting cells (APCs). The HSP-mediated antitumor immunity may be caused by a vaccine-like effect of HSP-peptide complexes released from dying tumor cells. The released HSP-peptide complexes encounter APCs that express specific receptors such as CD91 (61) . Interaction of HSP-peptide complexes with CD91 leads to receptor-mediated endocytosis, processing of the antigenic peptide by the endogenous MHC class I pathway, and the re-presentation of the peptide on the cell surface to the CD8-positive T cell receptor (61) . Additionally, HSPs function as a direct activator of APCs, stimulating cytokine secretion from monocytes and inducing the maturation of dendritic cells (DCs) through CD14 and/or CD91 receptors (62) . This cytokinelike ability of HSP70 to stimulate the innate immune system is independent of the peptides they chaperone, which suggests that HSP70 is a natural adjuvant. Ito et al. previously demonstrated that HSP70 expression following hyperthermia using MCLs induced antitumor immunity in T-9 rat glioma (50) .
A proposed scenario in which HSPs function during the successive stages of an antitumor response after hyperthermia is summarized and illustrated in Recently, a vaccine consisting of the autologous tumorderived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Woburn, MA, USA) has entered clinical trials, and the feasibility of treatment in metastatic melanoma patients was demonstrated (63) . Since the HSP-peptide complexes have to be extracted from tumors in the body, surgery is required in this therapeutic protocol. The surgery and extraction will be unnecessary if the hyperthermia is induced by MCLs. Udono and Srivastava (64) reported that the vaccination effect of HSP-peptide complexes was directly dependent on the dose. When the HSPs in the tumor are regarded as an antigen source, 1 g (approximately 10
8 cells) of tumor tissue may contain approximately 2 mg of HSP70. This represents a much higher dose than that used for the clinical trials. In the hyperthermic system using MCLs, the expression of HSP70 was enhanced, and tissue lysis via necrosis was observed throughout the tumor. This hyperthermic system can produce HSPpeptide complexes (possibly including HSPs such as HSP90 and gp 96), resulting in vaccination therapy. From these results and some hypotheses mentioned above, it is expected that hyperthermia can be combined with cytokines to improve the effectiveness of cancer therapy. In fact, combinations with cytokines (IL-2 and GM-CSF) (65), heat-inducible TNF-α gene therapy (66) , recombinant HSP70 (67), HSP70 gene therapy (68) , and dendritic cell therapy (69) , have been performed and significantly improved results were obtained, as shown in Fig. 6 .
VII. TISSUE ENGINEERING USING MAGNETIC NANOPARTICLES
Tissue engineering holds great promise as a means of resolving various issues surrounding organ transplantation (70) . Since cells labeled with magnetic nanoparticles can be manipulated using magnets, a novel tissue engineering methodology using magnetic force and functionalized magnetic nanoparticles referred to as Mag-TE was proposed by Ito et al. (71) . It is possible to culture the principal cell (the keratinocyte) of the epidermis and to use these cells to reconstitute human tissue (72, 73) . MCLs were used to magnetically label human keratinocytes, and Ito et al. (71) showed that magnetically labeled keratinocytes were accumulated using a magnet, and stratification was promoted by a magnetic force to form a sheet-like 3D construct. The addition of MCLs to human keratinocytes resulted in the rapid uptake of magnetite nanoparticles, and the amount of MCLs accumulated in the keratinocytes reached a maximum of 70% of the total added MCLs. Magnetically labeled keratinocytes were seeded into 24-well ultra low-attachment plates, the surface of which comprised a covalently bound hydrogel layer that is hydrophilic and neutrally charged. A neodymium magnet was placed under the plate. Keratinocytes without MCLs, or with MCLs in the absence of a magnet, did not attach onto the plates. In contrast, in the presence of the magnet, the keratinocytes with MCLs accumulated evenly throughout the wells (Fig. 7A) . Ito et al. (71) investigated whether the magnetically labeled sheets could be harvested using magnets. Figure 7B shows the procedure for harvesting keratinocyte sheets constructed by Mag-TE. The magnet positioned at the reverse side of the plate was removed. Then, a hydrophilically treated PVDF membrane was placed on top of a cylindrical alnico magnet (Fig. 7B-I) , and the magnet was positioned on the surface of the culture medium (Fig. 7B-II) . Due to the magnetic force, the keratinocyte sheets floated up to the surface of the culture medium without disruption and stuck to the PVDF membrane, as shown in Fig. 7B -III.
Tissues and organs in vivo often comprise several types of cell layers. Cell-cell interactions among these cell layers are important in order to maintain the normal physiology of organ systems. Heterotypic interactions play a fundamental role in liver function (74, 75) . Various 2D coculture systems of hepatocytes and nonparenchymal cells have been investigated (76, 77) . However, novel technologies are required to reconstruct the liver to enable it to function similarly to in vivo conditions. Ito et al. (78) applied the Mag-TE technique, in which a magnetic force was used to precisely place magnetically labeled cells onto target cells and to promote heterotypic cell-cell adhesion to form a 3D construct. Human aortic endothelial cells (HAECs) were magnetically labeled using MCLs, and the labeled HAECs were positioned onto a rat hepatocyte layer using a magnetic force. When a magnet was placed under the culture plate, HAECs accumulated on the hepatocyte layer. They found a construct consisting of a hepatocyte monolayer that expressed albumin under thick HAEC layers (Fig. 8A) . To determine the cellular function in the layered coculture system using the magnet, the hepatic albumin expression was measured (Fig. 8B) . Albumin secretion in the homotypic hepatocyte culture was undetectable beyond 5 d of culture. On the other hand, in the presence of a magnetic force, layered cocultures maintained a high level of albumin secretion throughout the study.
In conclusion, Ito et al. (71) developed a novel methodology to construct 3D tissues similar to those of in vivo tissues using magnetic nanoparticles and a magnetic force referred to as Mag-TE. This technology is presently being applied to various cell types such as human mesenchymal stem cells (79) and retinal pigment epithelial cells (80) . These results suggest that Mag-TE is a promising approach for tissue engineering.
VIII. CONCLUSION
In this article, we discuss the application of magnetic nanoparticles in magnetic separation, cancer diagnosis (MRI), hyperthermia and tissue engineering. These tech-FIG. 7. Construction and harvesting of multilayered keratinocyte sheets using magnetite nanoparticles and a magnetic force. (A) Photographs of hematoxylin and eosin-stained cross sections of keratinocyte sheets constructed using MCLs and a magnet. Keratinocytes were incubated in an MCL-containing medium for 4 h (50 pg/cell) and then seeded onto ultra low-attachment plates with a magnet. The keratinocytes were cultured using a low-calcium medium (HuMedia-KG2; calcium concentration, 0.15 mM) for 24 h. (B) Recovery of keratinocyte sheets using magnets. In order to harvest the magnetically labeled keratinocyte sheets, the magnet positioned on the reverse side of the 24-well ultra low-attachment plate was removed, and a hydrophilically treated PVDF membrane was placed on top of the cylindrical alnico magnet (I). The magnet was positioned at the surface of the culture medium (II). Due to the magnetic force, the keratinocyte sheets floated up to the surface of the culture medium and stuck to the PVDF membrane (III).
